About the Company
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DVAX News
How vaccine maker Dynavax tested itself and found a corporate cure
At the same time, Spencer said Dynavax is not limited to the adjuvant that brought the company here. It will continue to look for new technologies, new platforms and new collaborations ...
Q4 2023 Dynavax Technologies Corp Earnings Call
Rob Janssen; Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs; Dynavax Technologies Corp Kelly MacDonald; Chief Financial Officer, Senior Vice President ...
Dynavax Technologies Corporation (DVAX) Q4 2023 Earnings Call Transcript
Good day ladies and gentlemen and welcome to the Dynavax Technologies' Fourth Quarter ... At the end of the company's prepared remarks, we'll open the call for questions and provide specific ...
Dynavax Technologies (NASDAQ: DVAX)
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics.
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
EMERYVILLE, Calif., Feb. 22, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative ...
Dynavax Technologies Corp.
Earnings Per Share (TTM) A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding. Market Capitalization Reflects the total ...
Dynavax Technologies Corporation (0IDA.L)
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call Transcript February 22, 2024 Dynavax Technologies Corporation isn’t one of the 30 most popular stocks among hedge funds at the end ...
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2023 Earnings Call Transcript
Dynavax Technologies Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and gentlemen and ...
Dynavax Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Financial Guidance
EMERYVILLE, Calif., Feb. 22, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, ...
Loading the latest forecasts...